Sudheer Polisetty, MD
Geriatric Medicine · Las Vegas, NVNPI 1811211428
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 100 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. AbbVie accounts for 60.5% of it on its own, with 10 other manufacturers making up the rest. Reporting peaked in 2019 at $838 and has fallen 94.7% since, to $44 in 2024.
Across 100 payments — averaging $18.88 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$1K
- E.r. Squibb & Sons, L.L.C.$144
- Cvrx, Inc.$125
- Pfizer$107
- Johnson & Johnson$99
- ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$81
- plus $189 from 5 others
What the payments were for
- Food & beverage$1,888100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 74 | $1,143 |
| E.r. Squibb & Sons, L.L.C. | 3 | $144 |
| Cvrx, Inc. | 1 | $125 |
| Pfizer | 6 | $107 |
| Johnson & Johnson | 6 | $99 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 2 | $81 |
| Merck | 3 | $57 |
| Medtronic | 1 | $55 |
| AstraZeneca | 2 | $38 |
| Lundbeck LLC | 1 | $23 |
| Otsuka America Pharmaceutical, Inc. | 1 | $17 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Barostim Neo System$125
- CAMZYOS$118
How this compares
$1,888 in reported general payments places this provider in the 80th percentile of 36 geriatric medicine providers in Nevada.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 258 | $83,610 |
| JardianceEmpagliflozin | 93 | $29,809 |
| TrulicityDulaglutide | 49 | $24,322 |
| OzempicSemaglutide | 20 | $20,307 |
| XareltoRivaroxaban | 70 | $20,078 |
| Risperdal ConstaRisperidone Microspheres | 14 | $18,224 |
| Toujeo SolostarInsulin Glargine,hum.Rec.Anlog | 28 | $11,398 |
| JanuviaSitagliptin Phosphate | 27 | $10,976 |
| Breo ElliptaFluticasone/Vilanterol | 24 | $10,455 |
| FarxigaDapagliflozin Propanediol | 30 | $8,742 |
| Incruse ElliptaUmeclidinium Bromide | 24 | $8,452 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 12 | $7,800 |
| Lyumjev Kwikpen U-100Insulin Lispro-Aabc | 39 | $7,783 |
| AranespDarbepoetin Alfa In Polysorbat | 12 | $7,407 |
| BrilintaTicagrelor | 40 | $7,072 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis, Abrysvo | $107 | $89,291276 claims |
| Johnson & JohnsonXarelto, Risperdal Consta | $99 | $38,30284 claims |
| AstraZenecaFarxiga, Brilinta, Symbicort | $38 | $20,28983 claims |
| MerckJanuvia | $57 | $10,97627 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 36 geriatric medicine providers in Nevada.
Other geriatric medicine in Las Vegas
- Leonardo Gan-LimLas Vegas$10K
- Syed HussainLas Vegas$2K
- Alvin Bay LinLas Vegas$2K
- Roopa DaniLas Vegas$2K
- Ji YooLas Vegas$1K
- Ajay NellutlaLas Vegas$815
- Anthony ArslanLas Vegas$769
- Mike JeongLas Vegas$60
- Vincent ChuLas Vegas$46
- Roland PuaLas Vegas$43
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.